436141-39-8

Basic information

• Product Name: 3-cyclopentyl-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2(R)-(4-methylsulfanyl-phenyl)-propionamide
• Synonyms: 3-cyclopentyl-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2(R)-(4-methylsulfanyl-phenyl)-propionamide
• CAS NO: 436141-39-8
• Molecular Weight: 411.609
• Mol File: 436141-39-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-cyclopentyl-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2(R)-(4-methylsulfanyl-phenyl)-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-cyclopentyl-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2(R)-(4-methylsulfanyl-phenyl)-propionamide(436141-39-8)
• EPA Substance Registry System: 3-cyclopentyl-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2(R)-(4-methylsulfanyl-phenyl)-propionamide(436141-39-8)

Safety Data

• Hazardous Substances Data: 436141-39-8(Hazardous Substances Data)

Upstream product

• 436141-37-6 N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl-2-(4-methylsulfanyl-phenyl)-acetamide 
• 27935-87-1 cyclopentylmethyl Iodide 
• 7226-23-5 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
• 144-55-8 sodium hydrogencarbonate 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 

Downstream Products

• 588939-54-2 3-cyclopentyl-2(R)-(4-methylsulfanyl-phenyl)-N-pyrazin-2-yl-propionamide 
• 436142-06-2 N-(1H-benzoimidazol-2-yl)-3-cyclopentyl-2(R)-(4-methanesulfanyl-phenyl)-propionamide 
• 436141-42-3 3-cyclopentyl-2(R)-(4-methylsulfanyl-phenyl)-propionic acid 

Relevant articles and documents

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is aryl or heteroaryl; R2 is halogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R5 is as defined herein; Z is O, S, S(O), S(O)2, or NR5a; X is S, O, N, NR3, or CR3; Y is NCR4 or N4; R3, R4, and R5 are as defined herein; R8 is aryl or heteroaryl; R6 and R7 are independently H, halogen, or alkyl; m is 0 or 1; and n is 0 to 3, or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

Fused heteroaromatic glucokinase activators

Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes.